Chimeric antigen receptor T-cells targeting IL-1RAP: a promising new cellular immunotherapy to treat acute myeloid leukemia

BACKGROUND: Acute myeloid leukemia (AML) remains a very difficult disease to cure due to the persistence of leukemic stem cells (LSCs), which are resistant to different lines of chemotherapy and are the basis of refractory/relapsed (R/R) disease in 80% of patients with AML not receiving allogeneic t...

Descripción completa

Detalles Bibliográficos
Autores principales: Trad, Rim, Warda, Walid, Alcazer, Vincent, Neto da Rocha, Mathieu, Berceanu, Ana, Nicod, Clémentine, Haderbache, Rafik, Roussel, Xavier, Desbrosses, Yohan, Daguindau, Etienne, Renosi, Florain, Roumier, Christophe, Bouquet, Lucie, Biichle, Sabeha, Guiot, Melanie, Seffar, Evan, Caillot, Denis, Depil, Stephane, Robinet, Eric, Salma, Yahya, Deconinck, Eric, Deschamps, Marina, Ferrand, Christophe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Immune Cell Therapies and Immune Cell Engineering
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9272123/
https://www.ncbi.nlm.nih.gov/pubmed/35803613
http://dx.doi.org/10.1136/jitc-2021-004222

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9272123/
https://www.ncbi.nlm.nih.gov/pubmed/35803613
http://dx.doi.org/10.1136/jitc-2021-004222

Ejemplares similares